AGL

agilon health, inc.

13 filings tracked

healthcarehealthcare servicesSMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat

90%

bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression

70%

bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure

60%

bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat

90%

bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression

70%

bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure

60%

bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat

90%

bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression

70%

bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure

60%

bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat

90%

bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression

70%

bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure

60%

bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat

90%

bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression

70%

bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure

60%

bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat

90%

bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression

70%

bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure

60%

bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat

90%

bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression

70%

bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure

60%

bullishMay 6

Net income surged 304% year-over-year to $48.9 million.

earnings beat

90%

bullishMay 6

Medical margin expanded 16% to $148.9 million despite lower revenues.

margin expansion

70%

bullishMay 6

Appointment of Tim O'Rourke as CEO and President to lead scaling efforts.

management change

60%

bearishMay 6

Facing multiple securities class action lawsuits regarding financial misstatements.

regulatory action

50%

bullishMay 6

Net income surged 304% year-over-year to $48.9 million.

earnings beat

90%

bullishMay 6

Medical margin expanded 16% to $148.9 million despite lower revenues.

margin expansion

70%

bullishMay 6

Appointment of Tim O'Rourke as CEO and President to lead scaling efforts.

management change

60%

bearishMay 6

Facing multiple securities class action lawsuits regarding financial misstatements.

regulatory action

50%

bullishMay 6

Net income surged 304% year-over-year to $48.9 million.

earnings beat

90%

bullishMay 6

Medical margin expanded 16% to $148.9 million despite lower revenues.

margin expansion

70%

bullishMay 6

Appointment of Tim O'Rourke as CEO and President to lead scaling efforts.

management change

60%

bearishMay 6

Facing multiple securities class action lawsuits regarding financial misstatements.

regulatory action

50%

bullishMay 6

Net income surged 304% year-over-year to $48.9 million.

earnings beat

90%

bullishMay 6

Medical margin expanded 16% to $148.9 million despite lower revenues.

margin expansion

70%

bullishMay 6

Appointment of Tim O'Rourke as CEO and President to lead scaling efforts.

management change

60%

bearishMay 6

Facing multiple securities class action lawsuits regarding financial misstatements.

regulatory action

50%

bullishMay 6

Net income surged 304% year-over-year to $48.9 million.

earnings beat

90%

bullishMay 6

Medical margin expanded 16% to $148.9 million despite lower revenues.

margin expansion

70%

bullishMay 6

Appointment of Tim O'Rourke as CEO and President to lead scaling efforts.

management change

60%

bearishMay 6

Facing multiple securities class action lawsuits regarding financial misstatements.

regulatory action

50%

bullishMay 6

Net income surged 304% year-over-year to $48.9 million.

earnings beat

90%

bullishMay 6

Medical margin expanded 16% to $148.9 million despite lower revenues.

margin expansion

70%

bullishMay 6

Appointment of Tim O'Rourke as CEO and President to lead scaling efforts.

management change

60%

bearishMay 6

Facing multiple securities class action lawsuits regarding financial misstatements.

regulatory action

50%

Filing History

10-QMay 8, 2026

The Q1 2026 filing reveals a fund in a high-growth transition phase, balancing aggressive asset accumulation with the rising costs of leverage. While the surge in net investment income and the successful launch of the AGL EPCI I joint venture point toward a scalable and institutional-grade platform, the narrowing gap between earnings and distributions is a critical point of fragility. Investors are essentially betting on the fund's ability to maintain its 10.4% yield without eroding NAV. The transition to a perpetual-life BDC structure and the planned 2028 share repurchase program provide a long-term framework for value creation, but the immediate focus remains on the stability of the floating-rate portfolio in a shifting interest rate environment.

10-QMay 6, 2026

The Q1 2026 filing presents a stark dichotomy: a company that has successfully engineered a short-term profit surge by cutting its losses, versus a business whose long-term viability is questioned by a shrinking member base. Agilon has clearly improved its immediate cash flow and net income, proving that its platform can be profitable when focused on a smaller, higher-quality footprint. The successful execution of a reverse stock split to regain NYSE compliance provides a temporary reprieve from delisting risks. However, the long-term investment case hinges on whether Agilon can return to growth without sacrificing these new margins. The tension between the bull case of 'operational triage' and the bear case of 'market share erosion' will be decided by the company's ability to attract new members under the new leadership of Tim O'Rourke while managing a precarious debt structure and significant legal headwinds. For now, the company has bought itself time, but the underlying risk of payor concentration remains a critical vulnerability.